Gilead Acquires Repare's Cancer Drug for $30 Million
Gilead Sciences purchases RP-3467, a promising cancer treatment targeting BRCA mutations, from Repare Therapeutics in a deal worth up to $30 million.
/ 7 items
#GILD↓
Trump Administration Secures Drug Price Cuts from Nine Major Pharmaceutical Companies
Nine pharmaceutical giants including Merck and GSK agree to slash U.S. drug prices to match other wealthy nations under new Trump administration deals, offering discounts up to 70%.
Arcus and Gilead Halt Cancer Trial After Treatment Fails to Extend Patient Survival
Arcus Biosciences discontinues Phase 3 STAR-221 cancer trial after independent review finds experimental treatment unlikely to improve survival for gastric and esophageal cancer patients.
Anito-cel Shows High Efficacy and Impressive Two-Year Survival Rates in Relapsed/Refractory Multiple Myeloma
New data confirms Arcellx’s anito-cel is a powerful and safe CAR-T cell therapy for relapsed or refractory multiple myeloma, showing deep, durable responses.
Gilead’s Trodelvy Fails to Meet Main Goal in Breast Cancer Study but Shows Early Survival Trend
Gilead’s Trodelvy did not significantly improve progression-free survival in a key late-stage study for common breast cancer, though early data hints at a possible survival benefit.
Galapagos Shuts Down Cell Therapy Division After Failed Sale Attempts
Biotech firm Galapagos winds down cell therapy business affecting 365 jobs across 5 countries after unsuccessful sale attempts. Stock drops 15% on announcement.